DEA Adjusts Amphetamine and Methylphenidate Production Quotas for 2025
Published Date: 10/2/2025
Notice
Summary
The DEA is changing how much d-amphetamine and methylphenidate can be made in 2025 to meet medical needs better. This affects drug makers and helps ensure enough medicine is available without waste. The update is happening quickly to stick to legal deadlines, but it doesn’t change prices or when you get your meds.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13580 — Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put 7-hydroxymitragynine above a certain amount into Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just has this substance, bringing strict rules and penalties. The move aims to keep people safe while the government figures out the long-term plan.
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2025-19320 — Overhead Door Counterbalance Torsion Springs From China; Determinations
The U.S. has found that imports of overhead door counterbalance torsion springs from China are hurting American companies because they’re being sold too cheaply and getting unfair government help. This means extra duties will be applied to these imports to protect U.S. businesses like IDC Group and Iowa Spring Manufacturing. These changes kick in soon, aiming to level the playing field and support local jobs.
Next: 2025-19344 — Future of the HECM and HMBS Programs and Opportunities for Innovation in Accessing Home Equity
HUD wants to hear from senior homeowners and others about how to make reverse mortgages better and easier to use. These changes could help seniors tap into their home’s value more smoothly and keep the programs strong for the future. If you’re a senior or work with home loans, your ideas could shape updates coming soon that might affect money and timing.